BGIM
BMRN icon

Brandywine Global Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Brandywine Global Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$56.2M Buy
945,847
+39,817
+4% +$2.17M 0.38% 75
2025
Q3 		$49.1M Buy
+906,030
New +$51.8M 0.34% 88

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Brandywine Global Investment Management's BMRN Position: Q4 2025 in Review

Brandywine Global Investment Management increased its BioMarin Pharmaceuticals (BMRN) stake by 4.4% in Q4 2025, buying an estimated $2.17M and bringing the position to 945,847 shares worth $56.2M. The position accounts for 0.38% of the portfolio, ranked #75.

Brandywine Global Investment Management first reported a position in BMRN in Q3 2025 and has held it in 2 quarters since. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

  • Brandywine Global Investment Management held 945,847 shares of BioMarin Pharmaceuticals worth $56.2M as of Q4 2025.
  • Brandywine Global Investment Management bought 39,817 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $2.17M.
  • BioMarin Pharmaceuticals made up 0.38% of Brandywine Global Investment Management's portfolio in Q4 2025, its #75 holding.
  • Brandywine Global Investment Management first reported a position in BioMarin Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Brandywine Global Investment Management's 13F filing for Q4 2025, filed 11 Feb 2026.